These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34284316)

  • 1. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis.
    Lee H; Nakamura K; Narayanan S; Brown RA; Nash RA; Griffith LM; Steinmiller KC; Devine SM; Hutton GJ; Popat U; Racke MK; Georges GE; Bowen JD; Arnold DL
    Mult Scler Relat Disord; 2021 Sep; 54():103149. PubMed ID: 34284316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
    Lee H; Nakamura K; Narayanan S; Brown R; Chen J; Atkins HL; Freedman MS; Arnold DL
    Mult Scler; 2018 Jul; 24(8):1055-1066. PubMed ID: 28617152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
    Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Steinmiller KC; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stuve O; Arnold DL; Wener MH; Georges GE; Wundes A; Kraft GH; Bowen JD
    Neurology; 2017 Feb; 88(9):842-852. PubMed ID: 28148635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.
    Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stüve O; Arnold DL; Spychala ME; McConville KC; Harris KM; Phippard D; Georges GE; Wundes A; Kraft GH; Bowen JD
    JAMA Neurol; 2015 Feb; 72(2):159-69. PubMed ID: 25546364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis.
    Mariottini A; Stack EH; Nair G; Nozzoli C; Wu T; Marchi L; Boncompagni R; Repice AM; Fainardi E; Pasquale FD; Carlesi E; Saccardi R; Jacobson S; Massacesi L
    Mult Scler Relat Disord; 2024 Aug; 88():105745. PubMed ID: 38996712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    Weeda MM; van Nederpelt DR; Twisk JWR; Brouwer I; Kuijer JPA; van Dam M; Hulst HE; Killestein J; Barkhof F; Vrenken H; Pouwels PJW
    J Neurol; 2024 Jan; 271(1):355-373. PubMed ID: 37716917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gray matter atrophy is related to long-term disability in multiple sclerosis.
    Fisniku LK; Chard DT; Jackson JS; Anderson VM; Altmann DR; Miszkiel KA; Thompson AJ; Miller DH
    Ann Neurol; 2008 Sep; 64(3):247-54. PubMed ID: 18570297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis.
    Andorra M; Nakamura K; Lampert EJ; Pulido-Valdeolivas I; Zubizarreta I; Llufriu S; Martinez-Heras E; Sola-Valls N; Sepulveda M; Tercero-Uribe A; Blanco Y; Saiz A; Villoslada P; Martinez-Lapiscina EH
    JAMA Neurol; 2018 Oct; 75(10):1246-1255. PubMed ID: 29971335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-dependent cut-offs for pathological deep gray matter and thalamic volume loss using Jacobian integration.
    Opfer R; Krüger J; Spies L; Hamann M; Wicki CA; Kitzler HH; Gocke C; Silva D; Schippling S
    Neuroimage Clin; 2020; 28():102478. PubMed ID: 33269702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.
    Zivadinov R; Uher T; Hagemeier J; Vaneckova M; Ramasamy DP; Tyblova M; Bergsland N; Seidl Z; Dwyer MG; Krasensky J; Havrdova E; Horakova D
    Mult Scler; 2016 Nov; 22(13):1709-1718. PubMed ID: 26883943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets.
    Cortese R; Battaglini M; Sormani MP; Luchetti L; Gentile G; Inderyas M; Alexandri N; De Stefano N
    Eur J Neurol; 2023 Jan; 30(1):179-186. PubMed ID: 36168741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study.
    Dong X; Xu G; Wang J; Yin N; Meng N
    Mult Scler Relat Disord; 2022 Sep; 65():103838. PubMed ID: 35749960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of deep grey matter volume on cognition in multiple sclerosis.
    Lorefice L; Carta E; Frau J; Contu F; Casaglia E; Coghe G; Barracciu MA; Cocco E; Fenu G
    Mult Scler Relat Disord; 2020 Oct; 45():102351. PubMed ID: 32731200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study.
    Tiberio M; Chard DT; Altmann DR; Davies G; Griffin CM; Rashid W; Sastre-Garriga J; Thompson AJ; Miller DH
    Neurology; 2005 Mar; 64(6):1001-7. PubMed ID: 15781816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of gray-matter multiple sclerosis lesions using double inversion recovery, diffusion, contrast-enhanced, and volumetric MRI.
    Parra Corral MA; Govindarajan ST; Stefancin P; Bangiyev L; Coyle PK; Duong TQ
    Mult Scler Relat Disord; 2019 Jun; 31():74-81. PubMed ID: 30951968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voxel-wise assessment of progression of regional brain atrophy in relapsing-remitting multiple sclerosis.
    Battaglini M; Giorgio A; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    J Neurol Sci; 2009 Jul; 282(1-2):55-60. PubMed ID: 19286193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers.
    Bussas M; Grahl S; Pongratz V; Berthele A; Gasperi C; Andlauer T; Gaser C; Kirschke JS; Wiestler B; Zimmer C; Hemmer B; Mühlau M
    Mult Scler; 2022 May; 28(6):900-909. PubMed ID: 34591698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.
    Opfer R; Ostwaldt AC; Walker-Egger C; Manogaran P; Sormani MP; De Stefano N; Schippling S
    J Neurol; 2018 May; 265(5):1158-1165. PubMed ID: 29549466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep gray matter changes in relapsing-remitting multiple sclerosis detected by multi-parametric, high-resolution magnetic resonance imaging (MRI).
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Eur Radiol; 2021 Feb; 31(2):706-715. PubMed ID: 32851443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.